The split arrives after BioNTech and Genmab expanded their clinical collaboration in 2022 to research, develop and ...

For the second quarter in a row, Incyte has used its earnings results to significantly slim down its early-stage pipeline as ...

The fight against cancer is seeing a revolutionary shift with the emergence of PD-1/PD-L1 Inhibitors. These groundbreaking ...

Treatment responses to Xalkori were not affected by PD-L1 expression in patients with advanced non-small cell lung cancer and ...

In this study, we performed H3K27ac CUT&Tag sequencing, investigated the heterogeneity of SEs between two GC subtypes with differential growth patterns, and revealed the immune escape signatures ...

New research suggests that, among patients with HER2-negative breast cancer, ER-low and ER-negative tumors are biologically and molecularly similar to one another but often significantly different ...

PD-1 checkpoint proteins on T cells (blue) can bind to two different receptors: PD-L1 and PD-L2. There are many ways to climb a mountain. This saying especially rings true in cancer research ...

The combination led to an objective response rate (ORR) of 35.5% as first-line treatment among 31 HNSCC patients with a PD-L1 combined positive score (CPS) less than 1, according to results of the ...

Incyte is gunning for a first-in-class nod for PD-1 inhibitor Zynyz in anal cancer again after being turned away by the FDA ...

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or ...

BioNTech has parted ways with Genmab for the joint development of their cancer programmed-cell death 1 ligand-1 (PD-L1) therapy, acasunlimab (BNT311/GEN1046), as it reports major Q2 losses.